Author

K. A. Swanson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 10 Organism:human· 7 Research Focus:drug response / drug discovery· 2 Research Focus:benchmarking· 1 Assay:clinical cohort / trial· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Muik· 7 shared D. Cooper· 6 shared J. Zou· 6 shared M. Cutler· 6 shared P.-Y. Shi· 6 shared X. Xie· 6 shared H. Cai· 5 shared H. Xia· 5 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

A. Muik

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

J. Zou, C. Kurhade, S. Patel, N. Kitchin, K. Tompkins, M. Cutler, D. Cooper, Q. Yang, H. Cai, A. Muik, Y. Zhang, D.-Y. Lee, U. Sahin, A. S. Anderson, W. C. Gruber, , P.-Y. Shi

This study compares the neutralizing antibody responses induced by monovalent and bivalent BA.4/5 vaccines against multiple Omicron sublineages in individuals over 55 years old, finding the bivalent vaccine elicits stronger neutralization.

bioRxiv · Nov 17, 2022 · PreprintMicrobiology

Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, C. I. C. Couto, A. Gueler, V. Mampilli, G. J. Schmitt, J. Mottl, T. Ziegenhals, S. Fesser, J. Reinholz, F. Wernig, K.-G. Schraut, , U. Sahin

This study shows that exposure to BA.4/BA.5 spike glycoprotein enhances neutralizing antibody breadth against Omicron variants in vaccinated humans and mice.

bioRxiv · Sep 21, 2022 · PreprintImmunology

Anellovirus Structure Reveals a Mechanism for Immune Evasion

K. A. Swanson, S.-H. Liou, S. Delagrave, R. Hajiar, Y. Chang, N. Yozwiak, T. Ong, H. Rodgers, N. Cohen, Y. Zhang, N. Mukund Acharekar, S. Islam, L. Zaheb, C. Arze, H. Swaminathan, J. Pitts

This paper determines the structure of an anellovirus, revealing how its unique surface features enable immune evasion by hiding conserved epitopes and exposing diverse ones as decoys.

bioRxiv · Jul 1, 2022Biochemistry

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection

C. Kurhade, j. Zou, H. Xia, M. Liu, Q. Yang, M. Cutler, D. Cooper, A. Muik, U. Sahin, K. U. Jansen, P. Ren, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron sublineages and Deltacron by BNT162b2 vaccine or BA.1 infection, finding BA.4/5 shows highest evasion.

bioRxiv · Jun 5, 2022Microbiology

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine

H. Xia, J. Zou, C. Kurhade, H. Cai, Q. Yang, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron SARS-CoV-2 by two or three doses of the BNT162b2 vaccine, showing increased neutralization with three doses but reduced durability over time.

bioRxiv · Jan 21, 2022 · PreprintMicrobiology

BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants

J. Liu, Y. Liu, H. Xia, J. Zou, S. Weaver, K. A. Swanson, H. Cai, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, U. Sahin, X. Xie, P. R. Dormitzer, P.-Y. Shi

The paper assesses the neutralization ability of BNT162b2-elicited sera against SARS-CoV-2 variants, finding that all sera neutralize variants to titers of ≥80, indicating vaccine effectiveness against emerging strains.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera

X. Xie, Y. Liu, J. Liu, X. Zhang, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D. Cooper, V. D. Menachery, S. Weaver, P. Dormitzer, P.-Y. Shi

The paper evaluates the neutralization effect of BNT162b2 vaccine-elicited sera against SARS-CoV-2 variants with specific spike mutations.

bioRxiv · Jan 27, 2021Microbiology

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

A. Muik, A.-K. Wallisch, B. Saenger, K. A. Swanson, J. Muehl, W. Chen, H. Cai, R. Sarkar, O. Tuereci, P. R. Dormitzer, U. Sahin

The paper assesses the neutralizing activity of BNT162b2 vaccine-induced sera against SARS-CoV-2 B.1.1.7 pseudoviruses and finds equivalent neutralizing titers compared to the Wuhan strain.

bioRxiv · Jan 18, 2021Immunology

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

X. Xie, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D. Cooper, V. D. Menachery, S. D. Weaver, P. R. Dormitzer, P.-Y. Shi

The paper assesses the neutralizing activity of BNT162b2 vaccine-elicited sera against N501Y and Y501 SARS-CoV-2 variants, finding equivalent neutralizing titers.

bioRxiv · Jan 7, 2021 · PreprintMicrobiology

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. Gueler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, , M. R Gutman

This paper evaluates two BNT162b vaccine candidates in non-human primates, showing they are immunogenic and protect against SARS-CoV-2 infection.

bioRxiv · Dec 11, 2020 · PreprintImmunology